Literature DB >> 26196319

Definition of a dynamic laparoscopic model for the prediction of incomplete cytoreduction in advanced epithelial ovarian cancer: proof of a concept.

M Petrillo1, G Vizzielli2, F Fanfani2, V Gallotta2, F Cosentino2, V Chiantera3, F Legge4, V Carbone2, G Scambia2, A Fagotti5.   

Abstract

OBJECTIVE: To develop an updated laparoscopy-based model to predict incomplete cytoreduction (RT>0) in advanced epithelial ovarian cancer (AEOC), after the introduction of upper abdominal surgery (UAS). PATIENTS AND METHODS: The presence of omental cake, peritoneal extensive carcinomatosis, diaphragmatic confluent carcinomatosis, bowel infiltration, stomach and/or spleen and/or lesser omentum infiltration, and superficial liver metastases was evaluated by staging laparoscopy (S-LPS) in a consecutive series of 234 women with newly diagnosed AEOC, receiving laparotomic PDS after S-LPS. Parameters showing a specificity≥75%, PPV≥50%, and NPV≥50% received 1 point score, with an additional one point in the presence of an accuracy of ≥60% in predicting incomplete cytoreduction. The overall discriminating performance of the LPS-PI was finally estimated by ROC curve analysis.
RESULTS: No-gross residual disease at PDS was achieved in 135 cases (57.5%). Among them, UAS was required in 72 cases (53.3%) for a total of 112 procedures, and around 25% of these patients received bowel resection, excluding recto-sigmoid resection. We observed a very high overall agreement between S-LPS and laparotomic findings, which ranged from 74.7% for omental cake to 94.8% for stomach infiltration. At a LPS-PIV≥10 the chance of achieving complete PDS was 0, and the risk of unnecessary laparotomy was 33.2%. Discriminating performance of LPS-PI was very high (AUC=0.885).
CONCLUSIONS: S-LPS is confirmed as an accurate tool in the prediction of complete PDS in women with AEOC. The updated LPS-PI showed improved discriminating performance, with a lower rate of inappropriate laparotomic explorations at the established cut-off value of 10.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Advanced epithelial ovarian cancer; Laparoscopy; Primary debulking surgery

Mesh:

Year:  2015        PMID: 26196319     DOI: 10.1016/j.ygyno.2015.07.095

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  27 in total

1.  Predictive modeling for determination of microscopic residual disease at primary cytoreduction: An NRG Oncology/Gynecologic Oncology Group 182 Study.

Authors:  Neil S Horowitz; G Larry Maxwell; Austin Miller; Chad A Hamilton; Bunja Rungruang; Noah Rodriguez; Scott D Richard; Thomas C Krivak; Jeffrey M Fowler; David G Mutch; Linda Van Le; Roger B Lee; Peter Argenta; David Bender; Krishnansu S Tewari; David Gershenson; James J Java; Michael A Bookman
Journal:  Gynecol Oncol       Date:  2017-11-23       Impact factor: 5.482

2.  Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer.

Authors:  Nicole D Fleming; Alpa M Nick; Robert L Coleman; Shannon N Westin; Pedro T Ramirez; Pamela T Soliman; Bryan Fellman; Larissa A Meyer; Kathleen M Schmeler; Karen H Lu; Anil K Sood
Journal:  Obstet Gynecol       Date:  2018-09       Impact factor: 7.661

Review 3.  Novel Surgical Strategies in the Treatment of Gynecological Malignancies.

Authors:  Martina Aida Angeles; Carlos Martínez-Gómez; Federico Migliorelli; Marie Voglimacci; Justine Figurelli; Stephanie Motton; Yann Tanguy Le Gac; Gwénaël Ferron; Alejandra Martinez
Journal:  Curr Treat Options Oncol       Date:  2018-11-09

4.  Survival outcome and perioperative complication related to neoadjuvant chemotherapy with carboplatin and paclitaxel for advanced ovarian cancer: A systematic review and meta-analysis.

Authors:  Hiroko Machida; Hideki Tokunaga; Koji Matsuo; Noriomi Matsumura; Yoichi Kobayashi; Tsutomu Tabata; Masanori Kaneuchi; Satoru Nagase; Mikio Mikami
Journal:  Eur J Surg Oncol       Date:  2019-12-04       Impact factor: 4.424

Review 5.  Appropriate Recommendations for Surgical Debulking in Stage IV Ovarian Cancer.

Authors:  Jing-Yi Chern; John P Curtin
Journal:  Curr Treat Options Oncol       Date:  2016-01

6.  A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.

Authors:  Rudy S Suidan; Pedro T Ramirez; Debra M Sarasohn; Jerrold B Teitcher; Revathy B Iyer; Qin Zhou; Alexia Iasonos; John Denesopolis; Oliver Zivanovic; Kara C Long Roche; Yukio Sonoda; Robert L Coleman; Nadeem R Abu-Rustum; Hedvig Hricak; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2017-02-14       Impact factor: 5.482

Review 7.  Current Recommendations for Minimally Invasive Surgical Staging in Ovarian Cancer.

Authors:  Anna Fagotti; Federica Perelli; Luigi Pedone; Giovanni Scambia
Journal:  Curr Treat Options Oncol       Date:  2016-01

8.  A multimodality triage algorithm to improve cytoreductive outcomes in patients undergoing primary debulking surgery for advanced ovarian cancer: A Memorial Sloan Kettering Cancer Center team ovary initiative.

Authors:  Alli M Straubhar; Olga T Filippova; Renee A Cowan; Yulia Lakhman; Debra M Sarasohn; Ines Nikolovski; Jean M Torrisi; Weining Ma; Nadeem R Abu-Rustum; Ginger J Gardner; Yukio Sonoda; Oliver Zivanovic; Dennis S Chi; Kara Long Roche
Journal:  Gynecol Oncol       Date:  2020-06-06       Impact factor: 5.482

9.  Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer.

Authors:  Jean M Hansen; Anil K Sood; Robert L Coleman; Shannon N Westin; Pamela T Soliman; Pedro T Ramirez; Bryan M Fellman; Kathleen M Schmeler; Nicole D Fleming
Journal:  Gynecol Oncol       Date:  2018-10-23       Impact factor: 5.482

10.  18F-FDG-PET/CT based total metabolic tumor volume change during neoadjuvant chemotherapy predicts outcome in advanced epithelial ovarian cancer.

Authors:  Tuulia Vallius; Johanna Hynninen; Jukka Kemppainen; Victor Alves; Kari Auranen; Jaakko Matomäki; Sinikka Oksa; Johanna Virtanen; Seija Grénman; Annika Auranen; Marko Seppänen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-23       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.